RxDoctor Payments Data

Vishal Patel, MD

Interventional Cardiology · Peoria, AZNPI 1437147477

Payments from drug & device makers

$15,913in general payments, 2019–2025

Across 152 payments — averaging $104.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$12K
  • Abbott$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$556
  • Abiomed$476
  • ZOLL Circulation Inc$117
  • Medtronic$110
  • plus $905 from 15 others

What the payments were for

  • Speaking & faculty fees$10,60067%
  • Travel & lodging$7295%
  • Food & beverage$4,58429%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,913 in reported general payments places this provider in the 55th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$902,541
Medicare patients
1,382
Services billed
12,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,050$1,293,539
XareltoRivaroxaban132$179,562
EntrestoSacubitril/Valsartan31$40,723
Repatha SureclickEvolocumab37$38,870
BrilintaTicagrelor23$18,588
Metoprolol Succinate921$13,420
Nifedipine ErNifedipine224$7,990
Diltiazem 24hr Er (Cd)Diltiazem Hcl213$7,686
Flecainide Acetate128$6,353
Ranolazine ErRanolazine44$6,255
Carvedilol544$6,148
Midodrine Hcl61$6,022
Losartan Potassium505$5,641
Valsartan255$4,882
Digoxin181$4,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$72$1,293,5391,050 claims
Johnson & JohnsonXarelto$92$179,562132 claims
NovartisEntresto$11,820$40,72331 claims
AstraZenecaBrilinta$60$18,58823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →